Lantern Pharma Inc. (LTRN)

Market Cap	35.53M -10.2%
Revenue (ttm)	n/a
Net Income	-15.91M
EPS	-1.45
Shares Out	11.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	176,051
Open	3.160
Previous Close	3.090
Day's Range	3.040 - 3.320
52-Week Range	1.110 - 5.744
Beta	2.10
Analysts	Strong Buy
Price Target	20.00 (+530.92%)
Earnings Date	May 15, 2026

About LTRN

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2020
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: LTRN
• Website: https://www.lanternpharma.com

Analyst Summary

According to 2 analysts, the average rating for LTRN stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 530.92% from the latest price.

Price Target

$20.0

(530.92% upside)

Analyst Consensus: Strong Buy